Keros Therapeutics (KROS) News Today $13.96 +0.25 (+1.82%) Closing price 08/13/2025 04:00 PM EasternExtended Trading$13.96 +0.00 (+0.04%) As of 08/13/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Analysts’ Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (AMN), Keros Therapeutics (KROS) and Evolent Health (EVH)August 11 at 11:46 PM | theglobeandmail.comKeros Therapeutics (NASDAQ:KROS) Price Target Cut to $20.00 by Analysts at HC WainwrightAugust 11 at 2:40 AM | americanbankingnews.comWilliam Blair Cuts Earnings Estimates for Keros TherapeuticsAugust 11 at 2:01 AM | americanbankingnews.comLeerink Partnrs Has Negative Estimate for KROS Q3 EarningsAugust 11 at 2:58 AM | marketbeat.comWilliam Blair Predicts Lower Earnings for Keros TherapeuticsAugust 11 at 2:58 AM | marketbeat.comHC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00August 9, 2025 | marketbeat.comXTX Topco Ltd Acquires New Position in Keros Therapeutics, Inc. (NASDAQ:KROS)August 9, 2025 | marketbeat.comKeros to Exclusively Prioritize the Clinical Advancement of KER-065August 6, 2025 | globenewswire.comKeros Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comBrokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $30.56August 5, 2025 | americanbankingnews.comFederated Hermes Inc. Grows Position in Keros Therapeutics, Inc. (NASDAQ:KROS)August 3, 2025 | marketbeat.comKeros Therapeutics (KROS) Projected to Post Earnings on WednesdayJuly 31, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 31, 2025 | marketbeat.comCorton Capital Inc. Makes New $186,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS)July 28, 2025 | marketbeat.comKeros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of ElriterceptJuly 17, 2025 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 6, 2025 | marketbeat.comB of A Securities Downgrades Keros Therapeutics (KROS)June 11, 2025 | msn.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 11, 2025 | marketbeat.comKeros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: AnalystJune 10, 2025 | uk.finance.yahoo.com3KROS : Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline...June 10, 2025 | benzinga.comKeros Therapeutics (NASDAQ:KROS) Rating Lowered to "Neutral" at Bank of AmericaJune 10, 2025 | marketbeat.comKeros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to StockholdersJune 9, 2025 | finanznachrichten.deADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return ProposalJune 9, 2025 | prnewswire.comKeros Therapeutics (NASDAQ:KROS) Shares Gap Down - Here's What HappenedJune 9, 2025 | marketbeat.comKeros Announces Return of $375 Million in Excess Capital to StockholdersJune 9, 2025 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Stock Position Boosted by Two Sigma Investments LPJune 9, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Keros Therapeutics (KROS)June 7, 2025 | theglobeandmail.comKeros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare ConferenceJune 6, 2025 | globenewswire.comNuveen Asset Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)June 5, 2025 | marketbeat.comKeros Therapeutics' (KROS) "Neutral" Rating Reaffirmed at WedbushMay 31, 2025 | marketbeat.comKeros Therapeutics Discontinues Cibotercept Development in PAH and Announces Corporate RestructuringMay 30, 2025 | nasdaq.comKeros Therapeutics (NASDAQ:KROS) Trading Down 3.9% - Here's What HappenedMay 30, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 174,189 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)May 30, 2025 | marketbeat.comKeros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS TrialMay 29, 2025 | insidermonkey.comKeros Therapeutics, Inc.: Keros Therapeutics Announces TROPOS Topline Data and Corporate RestructuringMay 29, 2025 | finanznachrichten.deKeros Cutting 45% of Staff, Ending Development of Cibotercept in PAHMay 29, 2025 | marketwatch.comKeros falls after discontinuation of hypertension treatment trialMay 29, 2025 | msn.comKeros Therapeutics Announces TROPOS Topline Data and Corporate RestructuringMay 29, 2025 | globenewswire.comLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director NomineesMay 27, 2025 | finance.yahoo.comLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director NomineesMay 27, 2025 | globenewswire.comTFG Asset Management GP Ltd Invests $1.63 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)May 27, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Woodline Partners LPMay 26, 2025 | marketbeat.comJanus Henderson Group PLC Sells 77,803 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)May 26, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Stock Holdings Lifted by Millennium Management LLCMay 25, 2025 | marketbeat.comBNP Paribas Financial Markets Invests $730,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)May 25, 2025 | marketbeat.comTwinbeech Capital LP Acquires 114,175 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)May 24, 2025 | marketbeat.comNorthern Trust Corp Increases Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)May 24, 2025 | marketbeat.comADAR1 calls for Keros to release review results before voteMay 23, 2025 | uk.investing.comADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna SethMay 21, 2025 | prnewswire.comTema Etfs LLC Purchases Shares of 35,663 Keros Therapeutics, Inc. (NASDAQ:KROS)May 20, 2025 | marketbeat.com Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Media Mentions By Week KROS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼-0.090.71▲Average Medical News Sentiment KROS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼156▲KROS Articles Average Week Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Agios Pharmaceuticals News Bausch Health Cos News Denali Therapeutics News ImmunityBio News Tarsus Pharmaceuticals News Mesoblast News Disc Medicine News Adaptive Biotechnologies News IDEAYA Biosciences News Harmony Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access